膀胱機能不全に対する 1-methyl-5-chloroindoline methylbromideの効果 -二重盲検試験による臨床効果-

Abstract

1. The effect of 1-methyl-5-chloroindoline methylbromide (S-6) tablets on paralytic disorders of the bladder was compared with that of a placebo employing a double blind method. 2. Global assessment of the results by the Research Group indicated that a more marked effect was noted in the S-6-treated group than in the placebo-treated group. 3. Bladder function tests revealed that improvement of the first desire to void (FDV), maximum desire to void (MDV) and bladder capacity (Be) was more pronounced in the S-6-treated group than in the placebo-treated group. 4. As regards the subjective symptoms, improvement of desire to urinate was significantly more marked in the S-6-treated group than in the placebo-treated group. 5. When the effect of S-6 was evaluated by dividing paralytic disorders of the bladder into neurogenic disorders of the bladder having a certain neurogenic background factors and other types of paralytic disorders of the bladder (including hypotonic bladder, dysuria and enuresis), it was found that in the former group there was no significant difference in the effect between S-6 and the placeho but in the latter group the effectiveness of S-6 was noted. 6. There was no significant difference in the incidence of adverse reactions between the S-6-treated and placebo-treated groups. 7. In view of the above, it is considered that S-6 is effective against paralytic disorders of the bladder and it is expected that satisfactory clinical results will be produced with the drug in the future.